Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE DATED FEBRUARY 4, 2014 - UROLOGIX INC | urologix140417_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): February 4, 2014
Urologix, Inc.
(Exact name of Registrant as Specified in its Charter)
Minnesota
(State Or Other Jurisdiction Of Incorporation)
| 000-28414 | 41-1697237 | |
| (Commission File Number) | (I.R.S. Employer Identification No.) | |
|
14405 21st Avenue North Minneapolis, MN |
55447 | |
| (Address Of Principal Executive Offices) | (Zip Code) |
(763) 475-1400
Registrant’s Telephone Number, Including Area Code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Items under Sections 1 and 3 through 8 are not applicable and therefore omitted.
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on February 4, 2014 disclosing material non-public information regarding the Company’s results of operations for the second fiscal quarter of fiscal year 2014 ended December 31, 2013.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
| Exhibit No. | Description | |
| 99.1 | Press Release issued on February 4, 2014. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| UROLOGIX, INC. | |||
| By: | /s/ Brian J. Smrdel | ||
| Brian J. Smrdel | |||
| Chief Financial Officer | |||
Date: February 5, 2014